An Automated Algorithm for the Identification of Somatosensory Cortex Using Magnetoencephalography.

The localization of eloquent cortex is crucial for many neurosurgical applications, such as epilepsy and tumor resection. Non-invasive localization of these cortical areas using magnetoencephalography (MEG) is generally performed using equivalent current dipoles. While this method is clinically validated, source localization depends on several subjective parameters. This paper aimed to develop an automated algorithm for identifying the cortical area activated during a somatosensory task from MEG recordings. Our algorithm uses singular value decomposition to outline the cortical area involved in this task. For proof of concept, we evaluate our algorithm using data from 10 subjects with epilepsy. Our algorithm has a statistically significant overlap with the somatosensory cortex (the expected active area in healthy subjects) in 6 of 10 subjects. Having thus demonstrated proof of concept, we conclude that our algorithm is ready for further testing in a larger cohort of subjects.Clinical relevance- Our algorithm identifies the dominant cortical area and boundary of the cortical tissue involved in a task-related response.

Active feature elicitation: An unified framework.

We consider the problem of active feature elicitation in which, given some examples with all the features (say, the full Electronic Health Record), and many examples with some of the features (say, demographics), the goal is to identify the set of examples on which more information (say, lab tests) need to be collected. The observation is that some set of features may be more expensive, personal or cumbersome to collect. We propose a classifier-independent, similarity metric-independent, general active learning approach which identifies examples that are dissimilar to the ones with the full set of data and acquire the complete set of features for these examples. Motivated by four real clinical tasks, our extensive evaluation demonstrates the effectiveness of this approach. To demonstrate the generalization capabilities of the proposed approach, we consider different divergence metrics and classifiers and present consistent results across the domains.

Comparison of Chlorhexidine and Hydrogen Peroxide as Preprocedural Mouthrinse during Ultrasonic Scaling: A Triple-Blinded Randomized Controlled Clinical Trial.

Background: Every year, around 2 million people suffer from hospital-acquired infections worldwide. Aerosols are produced while performing ultrasonic scaling. They are potential source of infection and cross contamination. It can result in spread of several infections including hepatitis, HIV, SARS CoV 2, etc. Preprocedural rinse before scaling is considered an effective measure to reduce the microbial load in aerosols. Materials and Methods: This study was a triple-blinded randomized controlled trial performed on 90 participants diagnosed with chronic periodontitis. Random allocation of participants into three groups, i.e., Group-1, Group-2, and Group-3, was done, wherein 0.12% chlorhexidine (CHX), 1.5% hydrogen peroxide (HP), and distilled water (DW) were used, respectively, as preprocedural mouthrinse. The participants of each group were instructed to perform mouthrinse for 60 s before the start of ultrasonic scaling sessions. Blood agar plates were kept at three locations, i.e., operator's chest area, patient's chest area, and assistant's chest area for aerosol collection after scaling. Colony-forming units (CFUs) were counted for microbiological analysis. Results: Least number of CFUs was found in the CHX group, followed by HP and DW groups. Location wise, the patient's chest area had the highest CFU count and the least was at the assistant's chest area. CFU count between the groups was statistically significant. Conclusion: Preprocedural rinse using HP can effectively be used as a method to reduce dental aerosols generated during ultrasonic scaling.

Enumerating the role of properdin in the pathogenesis of IgA nephropathy and its possible therapies.

BACKGROUND: IgA nephropathy (IgAN) has become the most prevalent form of glomerulonephritis affecting almost 1.3% of the total population worldwide. It is an autoimmune disorder where the host autoantibody forms an immune complex with the defective galactose-deficient IgA1 and gets deposited at the mesangium and endocapillary region of glomeruli. IgA has the capability to activate alternative and lectin complement cascades which even aggravates the condition. Properdin is directly associated with IgAN by activating and stabilising the alternative complement pathway at the mesangium, thereby causing progressive renal damage. OBJECTIVE: The present review mainly focuses on correlating the influence of properdin in activating the complement cascade at glomeruli which is the major cause of disease exacerbation. Secondly, we have described the probable therapies and new targets that are under trials to check their efficacy in IgAN. METHODS: An in-depth research was carried out from different peer-reviewed articles till December 2020 from several renowned databases like PubMed, Frontier, and MEDLINE, and the information was analysed and written in a simplified manner. RESULTS: Co-deposition of properdin is observed along with IgA and C3 in 75%-100% of the patients. It is not yet fully understood whether properdin inhibition can attenuate IgAN, as many conflicting reports have revealed worsening of IgAN after impeding properdin. CONCLUSION: With no specific cure still available, the treatment strategies are of great concern to find a better target to restrict the disease progression. More research and clinical trials are required to find out a prominent target to combat IgAN.

A review on the effect of COVID-19 in type 2 asthma and its management.

BACKGROUND: COVID-19 is considered the most critical health pandemic of 21st century. Due to extremely high transmission rate, people are more susceptible to viral infection. COVID-19 patients having chronic type-2 asthma prevails a major risk as it may aggravate the disease and morbidities. OBJECTIVE: The present review mainly focuses on correlating the influence of COVID-19 in type-2 asthmatic patients. Besides, it delineates the treatment measures and drugs that can be used to manage mild, moderate, and severe symptoms of COVID-19 in asthmatic patients, thus preventing any exacerbation. METHODS: An in-depth research was carried out from different peer-reviewed articles till September 2020 from several renowned databases like PubMed, Frontier, MEDLINE, and related websites like WHO, CDC, MOHFW, and the information was analysed and written in a simplified manner. RESULTS: The progressive results were quite conflicting as severe cases of COVID-19 shows an increase in the level of several cytokines that can augment inflammation to the bronchial tracts, worsening the asthma attacks. Contradicting to this, certain findings reveal the decrease in the severity of COVID-19 due to the elevation of T-cells in type-2 asthmatic patients, as prominent reduction of T-cell is seen in most of the COVID-19 positive patients. This helps to counteract the balance of immune responses and hence ameliorate the disease progression. CONCLUSION: Asthmatic patients must remain cautious during the COVID-19 pandemic by maintaining all the precautions to stay safe due to limited research data. Future strategies should include a better understanding of asthmatic exacerbation and its relation to COVID-19.